Total trials
280
Active
15
Phase 3
67
Total enrollment
62,402
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nemolizumab | — | — | — | 17 | |||
| Vehicle cream | — | — | — | — | 3 | ||
| Trifarotene | — | — | — | — | — | 2 |
Next readouts
- 2026-08-31
- 2026-09
- 2026-10-26
- 2026-12-31
- 2028-05-28
- 2028-07-15
Top conditions
- Acne Vulgaris32
- Rosacea19
- Acne11
- Glabellar Frown Lines9
- Atopic Dermatitis7
- Plaque Psoriasis7
- Skin Irritation6
- Nasolabial Folds6
Frequently asked questions about Galderma R&D
- How many clinical trials does Galderma R&D have on ClinicalTrials.gov?
- Galderma R&D is listed as the lead sponsor on 280 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Galderma R&D's trials are in Phase 3?
- 67 of Galderma R&D's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Galderma R&D focus on?
- Galderma R&D's most-studied conditions on ClinicalTrials.gov are Acne Vulgaris, Rosacea, Acne, Glabellar Frown Lines, Atopic Dermatitis.
- When are Galderma R&D's next clinical trial readouts?
- Galderma R&D has 6 upcoming primary-completion readouts tracked here; the soonest is “Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis”, expected around 2026-08-31.